Navigation Links
Medicago succesfully expresses VLP antigen for A H1N1 strain
Date:5/12/2009

QUEBEC CITY, May 12 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully expressed a new VLP antigen ("H1 VLP") from the influenza A (H1N1) strain that caused the recent Influenza outbreak in North America and other countries. The antigen was expressed within 14 days of receiving the DNA sequence with the Company's VLP vaccine technology and Proficia(TM) manufacturing technology.

Initial results show that the new H1 VLP is comparable to other VLPs recently expressed by Medicago such as the New Caledonia strain (H1N1) and Brisbane strain (H1N1). The primary goal of this initiative was to confirm, in a real case-scenario, Medicago's initial development timelines. Medicago requires the genetic sequence of the virus, limiting delays that may happen with traditional systems. The H1 VLP will be purified in preparation for an immunogenicity study in mice. The Company expects results from this study in June, with the goal of confirming the immunogenic potential of this H1 VLP.

"We are thrilled with these initial results. They demonstrate that we can rapidly express an antigen from a new influenza strain without modifying our current technology and could potentially be a first responder solution in the face of a pandemic," said Louis-Philippe Vezina, Chief Scientific Officer of Medicago. "Our ultimate goal is to provide a rapid approach to vaccine production allowing for immediate access to the antigens of emerging influenza strains. Current influenza vaccine manufacturing technologies can take up to six months to produce a vaccine for a new strain. With our proprietary technology we believe we can potentially cut development time up to five months."

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
3. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
4. Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
5. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
6. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
7. Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing
8. Stretching silicon: A new method to measure how strain affects semiconductors
9. NIST stress tests probe nanoscale strains in materials
10. Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
11. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a leading provider of ... occasion with a strong presence at Bio-IT World Conference & Expo 2017 in ... invitation to all attendees to view posters on the entire range of ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... for advanced technology applications, has announced a facility expansion to accommodate its rapid ... square feet of new workspace and renovation of the existing areas. The expansion ...
(Date:5/23/2017)... Greifensee, Switzerland (PRWEB) , ... May 23, 2017 ... ... which forces machine manufacturers to re-engineer their control technology again and again. METTLER ... common problem for machine manufacturers. The videos illustrate how integration of the ACT350 ...
(Date:5/21/2017)... ... May 19, 2017 , ... ... educational conference of the American Association of Bioanalysts (AAB) and the College of ... Houston. The conference reinforces AAB’s commitment to excellence in clinical laboratory services and ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
Breaking Biology News(10 mins):